Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Vitrakvi

- PMLiVE

NHS England to bring forward flu and COVID-19 vaccine programmes

The change follows an announcement on the risks presented by the new BA.2.86 COVID-19 variant

- PMLiVE

NHS England to offer world-first seven-minute cancer treatment injection

Subcutaneous administration of Roche’s Tecentriq could cut treatment time by up to 75%

- PMLiVE

UK government allocates £250m for more NHS hospital beds in England

The funds will provide another 5,000 beds this winter to relieve pressure on hospitals and cut waiting times

- PMLiVE

NHS England to offer millions of children flu vaccines from September

The rollout is part of the NHS winter flu and COVID-19 vaccination programme

- PMLiVE

NHS launches plans to expand drug contracts to develop new life-saving antibiotics

New antibiotics could reduce death rates and ensure future pandemic preparedness

- PMLiVE

Bristol Myers Squibb’s Sotyktu recommended by NICE for plaque psoriasis

An estimated 1.8 million people in the UK are affected by some form of the condition

- PMLiVE

NHS to introduce world-first genetic blood-matching test for transfusion treatments

NHS Blood and Transplant will receive almost £1m in funding from NHS England

- PMLiVE

Role of pharmacists widened under England’s new GP recovery plan

The plan is expected to free up around 15 million GP appointments over the next two years

- PMLiVE

NHS England announces rare genetic disorder fast-tracking service

Patients with inherited white matter disorders will benefit from earlier diagnosis and specialist care

- PMLiVE

ABPI welcomes new NHS research guidance for integrated care systems

Included in the proposals are calls for a fixed rebate rate of 6.88% on all eligible NHS medicine sales to be paid by the industry

- PMLiVE

AstraZeneca’s Evusheld not recommended by NICE for COVID-19 prevention

The agency said there is not enough evidence of the drug’s effectiveness against current variants

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu recommended by NICE for advanced breast cancer

The treatment has been recommended for use within a managed access arrangement

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links